Imipenem

ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Imipenem is an ofp drug catalogued in DrugCentral. It was first approved by the FDA in 1985. DrugCentral lists 5 molecular targets, including Penicillin-binding protein 4, blaPER-2 and ponA. Recorded indications include Abdominal abscess, Acute exacerbation of chronic bronchitis, Bacterial endocarditis and Bacterial infection due to Klebsiella pneumoniae.

• Approval status: ofp (first approved 1985 by the FDA).
• Molecular targets: Penicillin-binding protein 4, blaPER-2, ponA and blaGES-13 (5 listed in DrugCentral).
• Indications: Abdominal abscess, Acute exacerbation of chronic bronchitis, Bacterial endocarditis, Bacterial infection due to Klebsiella pneumoniae and Bacterial pneumonia and others.
• ATC code: J01DH51 (Carbapenems).
• Molecular formula: C12H17N3O4S; molecular weight 299.35 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (28)

• Abdominal abscess
• Acute exacerbation of chronic bronchitis
• Bacterial endocarditis
• Bacterial infection due to Klebsiella pneumoniae
• Bacterial pneumonia
• Bacterial septicemia
• Bacterial urinary infection
• Diabetic Foot Infection
• Endometritis
• Enterobacter Pneumonia
• Female genital tract infection
• Gram-Negative Aerobic Bacillary Pneumonia
• Haemophilus influenzae pneumonia
• Infection caused by Acinetobacter spp resistant to carbapenem antimicrobial drugs
• Infection caused by Citrobacter spp resistant to carbapenem antimicrobial drugs
• Infection caused by Enterococcus spp resistant to carbapenem antimicrobial drugs
• Infection caused by Escherichia coli strain resistant to carbapenem antimicrobial drugs
• Infection caused by Pseudomonas aeruginosa strain resistant to carbapenem antimicrobial drugs
• Infection caused by Serratia spp resistant to carbapenem antimicrobial drugs
• Infection of bone
• Infection of skin AND/OR subcutaneous tissue
• Infectious disease of abdomen
• Infectious disorder of joint
• Inflammatory Disease of Female Pelvic Organs
• Lower respiratory tract infection
• Peritonitis
• Pneumonia due to Escherichia coli
• Pneumonia due to Streptococcus

Off-label uses (10)

• Anthrax
• Clostridium Perfringens Empyema
• Cutaneous anthrax
• Gas gangrene caused by clostridium perfringens
• Gastrointestinal anthrax
• Infection by Campylobacter fetus
• Inhalational anthrax
• Melioidosis
• Pseudomonas Respiratory Tract Infection in Cystic Fibrosis
• Pyrexia of unknown origin

Contraindications (4)

• Kidney disease
• Lesion of brain
• Pseudomembranous enterocolitis
• Seizure disorder

Mechanism & targets

Molecular targets (5)

Target	Gene	Action	Activity
Penicillin-binding protein 4	—	unknown	IC50 7.30
Beta-lactamase	blaPER-2	unknown	Ki 7.22
Penicillin-binding protein 1	ponA	unknown	IC50 7.00
Beta-lactamase GES-13	blaGES-13	unknown	IC50 6.82
Bacterial penicillin-binding protein	mrcA|mrcB|dacC|mrdA|ftsI|dacA|dacB	inhibitor	—

Regulatory approvals (3)

Date	Agency	Marketed as	Applicant	Orphan
2021-06-23	PMDA	—	MSD K.K.	Yes
2020-02-13	EMA	—	Merck Sharp & Dohme B.V.
1985-11-26	FDA	—	—

ATC classification

ATC code	Therapeutic hierarchy
J01DH51	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER BETA-LACTAM ANTIBACTERIALS › Carbapenems
J01DH56	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER BETA-LACTAM ANTIBACTERIALS › Carbapenems

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Drug resistance	384.4
Multiple organ dysfunction syndrome	295.6
Pathogen resistance	264.4
Septic shock	262.0
Seizure	212.6
Drug ineffective	202.1
Ototoxicity	177.2
Eosinophilia	156.4
Thrombocytopenia	147.7
Electrocardiogram QT prolonged	145.2
Pseudomonas infection	122.7
Rash maculo-papular	117.5

Chemical structure

• Molecular formula: C₁₂H₁₇N₃O₄S
• Molecular weight: 299.35 g/mol
• CAS number: 64221-86-9
• InChIKey: ZSKVGTPCRGIANV-ZXFLCMHBSA-N
• PubChem CID: 104838

C[C@@H](O)[C@@H]1[C@H]2CC(SCCNC=N)=C(N2C1=O)C(O)=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Imipenem used for?

DrugCentral lists the following indications for Imipenem: Abdominal abscess, Acute exacerbation of chronic bronchitis, Bacterial endocarditis, Bacterial infection due to Klebsiella pneumoniae, Bacterial pneumonia, Bacterial septicemia, Bacterial urinary infection and Diabetic Foot Infection and others.

How does Imipenem work?

Its molecular targets in DrugCentral include Penicillin-binding protein 4, blaPER-2, ponA and blaGES-13.

When was Imipenem first approved?

Imipenem was first approved by the FDA in 1985.

What is the chemical formula of Imipenem?

Imipenem has the molecular formula C12H17N3O4S and a molecular weight of 299.35 g/mol.

Sources

• DrugCentral drug card 1426 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL43708 — compound record and bioactivity
• PubChem CID 104838 — chemical identifiers
• DrugBank DB01598 — drug record
• FDA UNII 71OTZ9ZE0A — substance identity
• DailyMed: FDA labels for Imipenem — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.